Follow us:

REPRODIVAC - Next-generation vaccines and diagnostics to prevent livestock reproductive diseases of worldwide impact

Objectives

Main objectives of the project are:

1
To genetically engineer a rationally attenuated Brucella suis vaccine and develop improved differential diagnostic tests to aid porcine brucellosis surveillance programs
2
To develop novel viral vectored vaccines designed to elicit antibodies that broadly neutralise Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) and an immunoassay to better measure PRRSV neutralising antibodies.
3
To produce recombinant proteins to facilitate the identification and prioritisation of DIVA vaccine candidate antigens for Q fever and Ovine Enzootic Abortion (OEA), and companion diagnostic tests.
4
To refine the manufacture of a recently developed Chlamydia abortus subcellular chlamydial outer membrane complex (COMC) vaccine and its evaluation for commercialisation, and to produce a companion molecular diagnostic test.

These objectives will be reach by exploiting recombinant systems and apply the following cutting-edge approaches:

  • Reverse and structural vaccinology (‘reverse vaccinology 2.0’) to select and design both vaccine and diagnostic candidate antigens.
  • Relevant protein expression systems for the production of vaccine and diagnostic candidate antigens.
  • Mutagenesis and recombineering to produce rationally attenuated and viral vectored vaccines.
  • Molecular and serological diagnostic approaches for DIVA and set-up of PoC tests.
+Epitope mapping, Knowledge-guided choice of surface exposed, antigenic domains and epitopes, Al based prediction of antigen structure and multimerization, Structure determination by CryoEM, Mimitope design, Delivery of antigens & mimotopes as recombinant antigens or incorporated in viral vectors

REPRODIVAC has received funding from the European Union’s Horizon Europe research and innovation programme under Grant Agreement No. 101060813. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or other granting authorities. Neither the European Union nor the other granting authorities can be held responsible for them.

REPRODIVAC has received funding from the European Union’s Horizon Europe research and innovation programme under Grant Agreement No. 101060813. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or other granting authorities. Neither the European Union nor the other granting authorities can be held responsible for them.
Feedback